NCT00291889View on ClinicalTrials.gov

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions

Tuberculosis (TB)

Interventions

BIOLOGICAL

Mtb72F/AS02.

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00291889 - Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults. | Biotech Hunter | Biotech Hunter